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ABSTRACT 
Objective: Studies have provided evidence of heterogeneity within chronic fatigue syndrome 
(CFS), but few have used data from large cohorts of CFS patients or replication samples. 
Methods: 29 UK secondary-care CFS services recorded the presence/absence of 12 CFS-related 
symptoms; 8 of these symptoms were recorded by a Dutch tertiary service. Latent Class Analysis 
(LCA) was used to assign symptom profiles (phenotypes). Regression models were fitted with 
phenotype as outcome (in relation to age, sex, BMI, duration of illness) and exposure (in relation 
to comorbidities and patient-reported measures). 
Results: Data were available for 7,041 UK and 1,392 Dutch patients. Almost all patients in both 
cohorts presented with post-exertional malaise, cognitive dysfunction and disturbed/unrefreshing 
sleep, and these 3 symptoms were excluded from LCA. In UK patients, six phenotypes emerged: 
‘full’ polysymptomatic (median 8, IQR 7-9 symptoms) 32.8%; ‘pain-only’ (muscle/joint) 20.3%; 
‘sore throat/painful lymph node’ 4.5%; ‘oligosymptomatic’ (median 1, IQR 0-2 symptoms) 4.7%. 
Two ‘partial’ polysymptomatic phenotypes were similar to the ‘full’ phenotype, bar absence of 
dizziness/nausea/palpitations (21.4%) or sore throat/painful lymph nodes (16.3%). Women and 
patients with longer duration of illness were more likely to be polysymptomatic. Polysymptomatic 
patients had more severe illness and more comorbidities. LCA restricted to 5 symptoms recorded 
in both cohorts indicated 3 classes (polysymptomatic, oligosymptomatic, pain-only), which were 
replicated in Dutch data. 
Conclusions: Adults with CFS may have one of 6 symptom-based phenotypes associated with 
sex, duration and severity of illness, and comorbidity. Future research needs to determine whether 
phenotypes predict treatment outcomes, and require different treatments. 
 
Keywords: chronic fatigue syndrome; latent class analysis; phenotypes; symptom profiles 
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INTRODUCTION 
Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) or, more 
recently, systemic exertion intolerance disease (SEID) (Institute of Medicine, 2015), is defined as 
persistent or recurrent debilitating fatigue that is not lifelong, or the result of ongoing exertion, or 
alleviated by rest, or explained by other conditions, and which results in a substantial reduction in 
activity (NICE, 2007). CFS imposes a huge burden on patients, carers and families (Horton et al., 
2010, Nacul et al., 2011, Sabes-Figuera et al., 2010). In the UK, adults who attend NHS specialist 
CFS services have been ill for a median duration of 3 years, and half of those who were employed 
at the onset of their illness have ceased working (Collin et al., 2011). A meta-analysis of 
prevalence studies based on clinically-confirmed cases in several countries indicates a prevalence 
of 0.76% (95% CI 0.23% to 1.29%) (Johnston et al., 2013). 
 
CFS is an illness of unknown aetiology and pathogenesis, and of varied symptomatology (Prins et 
al., 2006). Heterogeneity in the symptom profile of CFS can be confusing for clinicians, fuelling 
debate over diagnostic criteria, and posing an obstacle to biomedical research that aims to find 
biomarkers of CFS (Jason et al., 2005). Several studies have investigated heterogeneity 
(phenotypes) in adult (Hickie et al., 2009, Hickie et al., 1995, Janal et al., 2006, Sullivan et al., 
2005, Sullivan et al., 2002, Vollmer-Conna et al., 2006, Wilson et al., 2001) and paediatric (May 
et al., 2010) CFS patients. Despite between-study variation in the factors analysed and the 
methods used, these studies have demonstrated some consistency in classifying CFS phenotypes, 
including: a ‘polysymptomatic’ phenotype; a ‘sore throat/painful lymph node’ phenotype; 
phenotypes classified according to the presence/absence of musculoskeletal pain; and a dose-
response effect in the number of symptoms and the overall severity of CFS. However, only one of 
the above studies conducted a replication analysis (Aslakson et al., 2009). 
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The relationship between CFS phenotypes and treatment outcomes remains relatively unexplored. 
Three studies have shown that CFS patients who present with pain symptoms have less favourable 
outcomes (Cella et al., 2011, Crawley et al., 2013, Knoop et al., 2007b). If symptom-based CFS 
phenotypes predict treatment outcomes, then simple decision-making algorithms based on 
symptom profiles could be used by clinicians and therapists to deliver individualised treatments.  
 
In our study, we aimed to delineate symptom-based CFS phenotypes using data from a large 
clinical cohort of CFS patients from the UK, and to replicate our results in a clinical cohort of 
Dutch CFS patients. We aimed to investigate how these phenotypes were related to age, sex, and 
duration of illness, common CFS comorbidities (migraine, irritable bowel syndrome, anxiety and 
depression), and patient-reported measures of illness severity and quality-of-life. 
 
METHODS 
UK CFS patient cohort 
Study population 
Patient data were extracted from the CFS National Outcomes Database (NOD). The NOD is a 
centralized repository of pseudonymised clinical assessment and patient-reported outcome data 
which are routinely collected by NHS specialist CFS services across England. The NOD has been 
hosted by the University of Bristol since 2006, primarily for the purpose of evaluating NHS adult 
and paediatric CFS services. For this study, we used data from patients assessed and treated by 29 
NHS services during the period 01/06/2010 to 31/05/2013. 
 
Symptoms, comorbidities and patient-reported measures 
Clinical teams either sent photocopies of clinical assessment forms and patient questionnaires to 
the NOD team in Bristol for data entry or they entered data into their own local database which 
were transferred electronically to the NOD team at regular intervals. A CFS diagnosis was made 
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(or confirmed) at an initial clinical assessment appointment in accordance with NICE guidelines 
(NICE, 2007). The latter include a set of 12 persistent/recurrent symptoms, namely: sleep 
disturbance/unrefreshing sleep; joint pain; muscle pain; headaches; painful lymph nodes; sore 
throat; cognitive dysfunction; post-exertional malaise; general malaise/flu-like symptoms; 
dizziness; nausea; palpitations. Clinicians recorded the presence/absence of each symptom, with 
the guidance that the symptom should have persisted/recurred during 4 or more consecutive 
months, did not predate the fatigue and was not caused by some other medical condition. The 
recording of symptomatology in NHS specialist CFS services is part of the overall triage and 
assessment process, with multidisciplinary input from clinicians and therapists who have extensive 
experience in the diagnosis and treatment of CFS. Clinicians also record the presence/absence of 6 
common comorbidities (migraine, Irritable Bowel Syndrome, Fibromyalgia, Chronic Regional 
Pain Disorder, depression, and anxiety), the patient’s height and weight, and the duration of illness 
(months since onset of chronic fatigue). At assessment patients complete standard questionnaires 
which provide quantitative measures of fatigue (Chalder Fatigue Scale  (Chalder et al., 1993)), 
physical function (RAND SF-36 (Ware and Sherbourne, 1992)), mood (Hospital Anxiety & 
Depression Scale (HADS) (Snaith, 2003)), pain (visual analogue pain rating scale), self-efficacy 
(Stanford Self-Efficacy for Managing Chronic Disease 6-Item Scale (Lorig et al., 2001)), 
sleepiness (Epworth Sleepiness Scale (Johns, 1991)), and quality-of-life (EQ-5D (EuroQol, 
1990)). Psychiatric comorbidity that could explain the presence of fatigue was ruled out by 
clinical interview at the specialist service with experienced clinicians, using the HADS 
questionnaire. 
 
Dutch CFS patient cohort (replication sample) 
Study population 
The Dutch cohort comprised adults diagnosed with CFS at a tertiary specialist care centre during 
the period 2007-2012 in accordance with Centers for Disease Control and Prevention (CDC) 
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criteria (Fukuda et al., 1994, Reeves et al., 2003) and Dutch guidelines (CBO, 2013, Prins et al., 
2003). A Checklist Individual Strength (CIS20-R) fatigue severity subscale score ≥35 (Vercoulen 
et al., 1994) and a Sickness Impact Profile (SIP) score ≥700 were used as operational criteria for 
fatigue that was severe enough to cause substantial functional impairment (Knoop et al., 2007a). 
Consultants of the outpatient clinic of the Department of Internal Medicine assessed the medical 
status of all patients and decided whether patients had been sufficiently evaluated to rule out a 
medical explanation for the fatigue. If patients had not been sufficiently examined, they were seen 
for full physical examination, case history evaluation and laboratory tests. Psychiatric comorbidity 
that could explain the presence of fatigue was ruled out by clinical interview at the specialist 
service with experienced clinical psychologists using Beck Depression Inventory for Primary Care 
(BDI-PC) (Beck et al., 1997, Brown et al., 2012) and SCL-90 (Arrindell et al., 2004) 
questionnaires. 
 
 Symptoms, comorbidities and patient-reported measures 
CDC diagnostic criteria include a set of 8 persistent/recurrent symptoms occurring during 6 or 
more consecutive months: unrefreshing sleep; pain in several joints; muscle pain; headache; tender 
lymph nodes; sore throat; impaired memory; impaired concentration; and feeling ill after exertion. 
Patients were asked “Which of the following complaints did you experience during the last 6 
months?” and, if affirmative, whether the symptom had been experienced for “less than” or 
“longer than” 6 months. We coded responses of “Not at all” and “Sometimes (each month)” as 
‘symptom absent’ and responses of “Sometimes (each week)” and “Daily” as ‘symptom present’. 
The latter also required the symptom to have been experienced for “longer than” 6 months. ‘Post-
exertional malaise’ was in response to a question asking whether symptoms were worse after 
physical effort; ‘Cognitive dysfunction’ was based on an affirmative response to one or both of 
two separate questions about forgetfulness and concentration; ‘Sleep disturbance’ was in response 
to a question asking whether the patient woke up unrefreshed. Responses were recorded by self-
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completed questionnaire. At assessment patients complete standard questionnaires which provide 
quantitative measures of: fatigue (Chalder Fatigue Scale (Chalder et al., 1993) and CIS20-R 
(Vercoulen et al., 1994)); physical functioning (RAND SF-36 (Ware and Sherbourne, 1992)); 
mood (BDI-PC); and a 7-item self-efficacy scale (Prins et al., 2001). 
 
Ethical approvals 
The North Somerset & South Bristol Research Ethics Committee determined that collection and 
analysis of these CFS patient data did not require ethical review by an NHS Research Ethics 
Committee or approval by NHS Research and Development offices (REC ref. 07/Q2006/48). The 
medical-ethical committee of the Radboud University Nijmegen Medical Centre ruled that the 
collection and analysis of Dutch CFS patient data did not require ethical review. Dutch CFS 
patient data were collected as part of routine clinical practice.   
 
 Statistical methods 
CFS phenotypes (primary and replication analyses) 
Our latent class analysis (LCA) was based on symptoms recorded in UK and Dutch patient data. 
We planned to conduct our primary analysis using 12 symptoms recorded in UK patients, and our 
replication analysis using the restricted set of 8 symptoms recorded in both UK and Dutch patient 
data. All analyses were carried out using Mplus version 7.11 (Muthén and Muthén, 2013). 
LCA identifies subtypes of related cases (latent classes, or ‘phenotypes’) from multivariate 
categorical data – in this case, responses to questions about presence/absence of each symptom 
(Rabe-Hesketh and Skrondal, 2008). LCA aims to determine the minimum number of latent 
classes that describe the observed patterns of responses in the data. In LCA, each individual is 
‘assigned’ (probabilistically) to one of a pre-defined number of discrete latent classes on the basis 
of their responses to the symptom questions. The optimum class solution, i.e. the optimum number 
of classes, is selected by inspection and comparison of various model fit statistics (Nylund et al., 
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2007), including: 1) Bayesian Information Criterion (BIC); 2) bivariate model fit - a test of the 
conditional independence assumption (within each class, there should be no association of one 
symptom with another, because all associations between symptoms are accounted for by class 
membership); 3) entropy - a measure of how well individuals have been classified (based on class 
membership probabilities) - a value of ‘1’ indicates perfect separation of the classes; 4) Lo-
Mendell-Rubin adjusted likelihood ratio test for c compared with c-1 classes; and 5) bootstrapped 
likelihood ratio test (BLRT) for c compared with c-1 classes. Selection of the optimum latent class 
solution, particular when the statistical selection criteria are inconclusive, may also be informed by 
subjective input, including: clinical/biological plausibility, prior knowledge of likely heterogeneity 
within CFS, and the clinical and epidemiological utility of any solution. 
 
Factors associated with CFS phenotypes 
The associations of risk factors with CFS phenotype were estimated using a series of multinomial 
logistic regression models. Parameter estimates were obtained using an implementation in Mplus 
of the 3-step method proposed by Jeroen Vermunt (Asparouhov and Muthen, 2013, Vermunt, 
2010). Models were derived initially using the normative latent class as the baseline category for 
the outcome.  The models were then re-parameterized to investigate possible differences between 
the classes, using each class in turn as reference class. This method has been shown to produce 
less biased estimates than traditional 3-step methods, such as probability weighting and modal 
class assignment, whilst avoiding the problem of covariates impacting on the measurement model 
itself (Vermunt, 2010). 
 
Associations of CFS phenotypes with comorbidities and patient-reported measures 
The associations of CFS phenotypes with comorbidities as binary outcomes (migraine, IBS, 
anxiety, depression and ‘other’) were estimated as odds ratios using a 3-step approach in Mplus as 
described above. Estimates were adjusted for the potential confounding effects of age, sex and 
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duration of illness. Mean values of patient-reported measures (fatigue, physical function, 
depression, anxiety, pain, sleepiness, self-efficacy, and quality-of-life) across the latent classes 
were estimated using the same 3-step approach. Evidence for overall variation of each patient-
reported measure across latent classes was obtained using a Wald test, assuming homogeneous 
variance. 
 
CFS phenotypes (sensitivity analyses) 
We decided a priori not to include in our LCA factors which we considered to be: a) patient 
characteristics potentially associated with class assignment (age, sex, duration of illness, BMI); b) 
secondary to, or co-occurring with, CFS, i.e. comorbidities; c) markers of severity of CFS, i.e. 
patient-reported continuous measures of fatigue, physical function, self-efficacy, etc. However, we 
did perform sensitivity analyses in which we added some of these factors to our symptom-based 
LCA, specifically: sleep apnoea/hypnoea (for which we used, by proxy, an Epworth Sleepiness 
Scale score ≥11); obesity (BMI ≥30kg/m2); comorbid anxiety (from medical history or HADS 
anxiety score ≥11); and comorbid depression (from medical history or HADS depression score 
≥11). The aim of these sensitivity analyses were to investigate whether these additional factors 
contributed to further delineation of CFS phenotypes and/or were consistent with findings from 
studies which had used factors other than symptoms. 
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RESULTS 
UK and Dutch patient characteristics 
Data were available for 7,041 UK and 1,392 Dutch patients. Demographic characteristics of the 
UK and Dutch patients were broadly similar (Table S1), although the Dutch cohort was slightly 
younger (mean age 37.2 (95% CI 36.6 to 37.9) years, compared to 40.5 (40.2 to 40.7) years, 
P<0.001) and had a slightly higher proportion of men (25.6% compared to 22.1%, P=0.004). 
Dutch patients had lower Chalder fatigue (median 25 compared to 28) and higher SF36 physical 
function (median 55 compared to 40, where high score = less disabled) scores (P<0.001 for both).  
 
CFS symptoms in UK and Dutch (NL) patients 
Symptoms of post-exertional malaise (UK 96.5%, NL 87.5%), cognitive dysfunction (UK 94.1%, 
NL 92.1%), and sleep disturbance (UK 95.3%, NL 96.8%) occurred in almost all patients in both 
cohorts (Table 1). These 3 symptoms were excluded from the primary and replication analyses, 
because they did not contribute to differentiation of latent classes. Hence, the primary analysis in 
UK patient data was based on 9 symptoms, and the replication analysis in UK and Dutch data on 5 
symptoms. A lower proportion of male and female Dutch patients presented with each symptom 
than their same-sex UK counterparts (all P≤0.006), with the exception of cognitive dysfunction 
and sleep disturbance among men, and sleep disturbance among women, which occurred equally 
in both cohorts. 
 
CFS phenotypes in UK patients (primary analysis) 
An optimal 6-class solution was identified from the 9 symptoms remaining after exclusion of post-
exertional malaise, cognitive dysfunction, and sleep disturbance (Figure 1, Table S2): 32.8% of 
patients presented with a ‘full’ polysymptomatic phenotype (median 8, IQR 7-9 symptoms); 
20.3% with a muscle/joint ‘pain-only’ phenotype (median 3, IQR 2-4 symptoms); 4.5% with a 
‘sore throat/painful lymph node’ polysymptomatic phenotype (median 4, IQR 3-5 symptoms); and 
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4.7% with an ‘oligosymptomatic’ phenotype (median 1, IQR 0-2 symptoms). The other 2 ‘partial’ 
polysymptomatic phenotypes were similar to the ‘full’ phenotype, differentiated largely by 
absence of dizziness/nausea/palpitations (‘Non-dizzy polysymptomatic’; 21.4%; median 6, IQR 5-
6 symptoms) or absence of painful lymph nodes/sore throat (‘Non-throat/lymph 
polysymptomatic’; 16.3%; median 5, IQR 5-6 symptoms). 
 
Associations of age, sex, BMI, and duration of illness with CFS phenotypes (UK patients) 
Patients presenting with a polysymptomatic phenotype were more likely to be female and to have 
been ill for longer, compared with patients presenting with the oligosymptomatic phenotype 
(Table 2). These associations were most evident for the ‘full’ polysymptomatic phenotype: the 
odds of presenting with this phenotype were almost 4 times higher among women versus men 
(odds ratio (OR) 3.75 (95% CI 2.78 to 5.06)); and more than 2 times higher among patients who 
had been ill for ≥10 versus 1-2 years (OR 2.36 (1.39 to 4.00)). There were no clear patterns in the 
association of age with phenotype, although the oldest (60+ years) versus youngest (18-29 years) 
patients had lower odds of presenting with the ‘full’ polysymptomatic phenotype and with 2 of the 
3 ‘partial’ polysymptomatic phenotypes. Obese patients (BMI ≥30kg/m2) were almost 3 times 
more likely to present with a pain-only (OR 2.75 (1.33, 5.74)) than with an oligosymptomatic 
phenotype, and also had higher odds of presenting with ‘full’ and ‘non-dizzy’ polysymptomatic 
phenotypes. 
 
Associations of CFS phenotypes with comorbidities (UK patients) 
Patients presenting with a polysymptomatic phenotype were more likely to have a comorbid 
diagnosis of Irritable Bowel Syndrome (IBS), compared to patients presenting with the 
oligosymptomatic phenotype (Table 3). The ‘full’ polysymptomatic phenotype had the highest 
risk of comorbid IBS (OR 4.81 (3.12 to 7.40)) followed by patients presenting with a ‘non-
throat/lymph’ phenotype, i.e. all symptoms except painful lymph nodes and sore throat (OR 3.47 
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(2.20 to 5.49)). This pattern was also evident for migraine and ‘other’ (not specified) 
comorbidities. Comorbid anxiety and depression were associated only with the ‘full’ 
polysymptomatic phenotype: OR 1.54 (1.11 to 2.15) and OR 1.56 (1.11 to 2.20), respectively. 
Fibromyalgia as a comorbidity was reported for 39% of patients classified with the ‘pain-only’ 
phenotype, and 31% of those with the full polysymptomatic phenotype; too few patients (<3%) 
with the oligosymptomatic phenotype had comorbid fibromyalgia to allow estimation of odds 
ratios with this as the reference group. 
 
Associations of CFS phenotypes with patient-reported measures (UK patients) 
There was strong evidence of variation in each of the patient-reported measures across the 6 
classes (Table 4). Patients who presented with the ‘full’ polysymptomatic phenotype had greater 
severity of illness (lower physical function score), higher levels of pain, anxiety, and depression, 
and worse quality-of-life (lower EQ-5D and self-efficacy scores) than ‘oligosymptomatic’ 
patients.  Although ‘oligosymptomatic’ patients had less physical disability (high SF-36 scores), 
their mean level of fatigue was similar to polysymptomatic patients. Patients presenting with the 
‘sore throat/painful lymph node’ phenotype (Class 4) reported remarkably low fatigue scores, and 
their physical function scores were higher than those reported by oligosymptomatics, i.e. they 
were less physically disabled. 
 
Sensitivity analyses (UK patients) 
Sensitivity analyses showed that two factors included in several other studies namely, sleep 
apnoea/hypnoea (Epworth Sleepiness Scale score ≥11) and obesity (BMI ≥30kg/m2), did not 
contribute to further differentiation of the phenotypes, but merely confirmed the associations 
found in our primary analyses between polysymptomatic and pain-only phenotypes and higher 
odds of obesity and levels of daytime sleepiness, i.e. LCA based on 9 symptoms plus sleep 
apnoea/hypnoea and obesity yielded a 6-class solution in which the probabilities of sleep 
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apnoea/hypnoea and obesity increased in order from the lowest (oligosymptomatic) to highest (full 
polysymptomatic) (Table S4, Figure S1). 
 
When we added presence/absence of other comorbidities to our LCA, the pattern that emerged 
was for each of the six previously-defined symptom-based phenotypes to be further subdivided 
according to the presence/absence of each comorbidity. This led to a multiplicity of classes, with 
model fit statistics tending towards a 12-class solution (Table S3). The 6-class solution had 
symptom profiles matching those found in our main (symptom-only) analysis, with probabilities 
for each comorbidity being similar to those obtained in our analysis of associations of CFS 
phenotypes with comorbidities, i.e. by treating comorbidities as binary outcomes (Table S4, 
Figure S1). 
 
CFS phenotypes among UK and Dutch patients (replication analysis) 
LCA based on the restricted set of 5 symptoms which had been recorded in both Dutch and UK 
patients, i.e. excluding post-exertional malaise, cognitive dysfunction and sleep disturbance, 
indicated 3- and 4-class solutions in the UK data, both of which were replicated in the Dutch data 
(Table S5). The classes in the 3-class solutions were aligned with the ‘full’ polysymptomatic, 
‘pain only’ and ‘oligosymptomatic’ phenotypes that we had identified within the 6-class solution 
based on 9 symptoms in the UK patient data (Figure 2). The 4-class solutions for both cohorts 
were similar in that they delineated a ‘sore throat/painful lymph node/headache’ phenotype, as 
seen in the UK patient data 6-class 9-symptom solution (Figure 3). 
 
The proportions of patients assigned to each of the classes differed between the UK vs Dutch (NL) 
cohorts, e.g.: ‘full’ polysymptomatic 53.2% UK vs 25.4% NL; ‘pain-only’ 37.6% UK vs 51.9% 
NL; ‘oligosymptomatic’ 9.2% UK vs 22.6% NL (Figure 2). The almost 3-fold higher odds of 
women in the UK cohort having the ‘full’ polysymptomatic vs oligosymptomatic phenotype (OR 
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2.76 (2.23 to 3.42)), and the 50% lower odds of being in the oldest (60+ years) compared with the 
youngest (18-29 years) age groups (OR 0.50 (0.33 to 0.75)), were not evident in the Dutch cohort 
(Table 5). In both cohorts, each of the four patient-reported measures (fatigue, physical function, 
depression, and self-efficacy) in ‘full’ polysymptomatic patients were indicative of more severe 
illness and worse quality-of-life than was reported by oligosymptomatic patients (Table 5). 
 
DISCUSSION 
In the largest study of CFS patients to date, we found 6 phenotypes based on 9 common symptoms 
in CFS patients attending UK specialist services, and we replicated 3 phenotypes (based on 5 of 
these symptoms) in CFS patients attending a Dutch specialist service. It is clear from both patient 
cohorts that post-exertional malaise, cognitive dysfunction and disturbed/unrefreshing sleep were 
near universal symptoms, although this may reflect the diagnostic processes in each country. We 
found that symptom-based CFS phenotypes were strongly associated with patient-reported 
measures of illness severity and with comorbidities, suggesting that different approaches to 
treatment of CFS might be warranted. 
 
The main strengths of our study lie in the large sample size of our UK patient cohort, in our 
replication of CFS phenotypes and their associations with patient-reported measures in a different 
health care setting, and that all patients were diagnosed at specialist CFS services in either 
secondary (UK) or tertiary (NL) specialist CFS facilities. Of the dozen or so CFS phenotype 
studies published since 1995 (Jason et al., 2005), only one had a sample size approaching ours: a 
multi-country study by Hickie et al which was based on a sample of 37724 people, of whom 1958 
were formally diagnosed with CFS (Hickie et al., 2009). A twin registry-based study in Sweden 
was based on a sample of 5,330 (Sullivan et al., 2005), but only 732 (2.4%) were classified as 
having a CFS-like illness (Evengard et al., 2005). Only one previous study has conducted a 
replication analysis, using a relatively small sample (Aslakson et al., 2009). 
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Another strength of our study is that, unlike previous studies (with the exception of Janal et al. 
(2006)), our analysis was based on the presence/absence of a core set of 12 commonly-reported 
CFS symptoms. Previous CFS phenotype studies have been based on longer lists of, for example, 
38 (Hickie et al., 1995), 55 (Wilson et al., 2001), and 32 (Sullivan et al., 2002) typical and 
atypical symptoms. We adopted our approach because symptom-based phenotypes could, in 
principle, be identified as part of routine clinical practice in UK and Dutch specialist CFS 
services, where these symptoms are already routinely recorded when patients are assessed. 
Whether such phenotypes are clinically important in practice remains to be determined, by 
investigating how they relate to treatment response. Precedent for the importance of improved 
subtyping in advancing our understanding of pathophysiology and personalised treatments include 
the differentiation of depressive disorders into unipolar and bipolar affective conditions (with 
different treatments indicated for each, i.e. antidepressants contra-indicated for bipolar 
depression), and juvenile idiopathic arthritis (JIA) being subdivided into oligo- and polyarthritis 
phenotypes. In JIA, phenotypic analyses revealed subtypes which were more homogeneous than 
those defined by expert consensus, and which had very distinct disease trajectories (Eng et al., 
2014). In depressive disorders, latent class analysis indicated subtypes (differentiated by 
symptoms such as insomnia and appetite) which predicted remission after citalopram treatment 
(Ulbricht et al., 2015). 
 
Differences in patient characteristics and CFS phenotypes between the two cohorts could be 
attributable to differences in UK and Dutch referral pathways, clinical settings and diagnostic 
criteria. Dutch patients were diagnosed in accordance with CDC criteria (Fukuda et al., 1994, 
Reeves et al., 2003), which require fatigue of ≥6 months’ duration plus the presence of at least 4 
symptoms (including feeling ill after exertion, impaired memory or concentration, and 
unrefreshing sleep), compared to fatigue of ≥4 months’ duration and no specific symptom 
requirements in UK NICE guidelines (NICE, 2007). Dutch patients also had to exceed thresholds 
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for fatigue (CIS20-R) and disability (SIP) (Knoop et al., 2007a). However, the substantial 
differences in the proportions of Dutch versus UK patients presenting with each CFS phenotype in 
our replication analyses are perhaps more likely to be a consequence of other differences in the 
assessment pathway, in particular, more rigorous psychological assessment to exclude somatic or 
psychiatric disorders. 
 
If Dutch patients with comorbidities were more likely to be excluded, this may explain the lower 
proportion of Dutch versus UK CFS patients with the ‘full’ polysymptomatic phenotype, given 
that patients with this symptom profile were more likely to have comorbidities. UK patient data 
for our study were obtained from NHS specialist CFS services, in which an average of 80% of 
referred patients were diagnosed with CFS (Collin et al., 2012). Case note review has shown that 
40-50% of referrals to such services could have alternative diagnoses, mainly of psychological or 
sleep disorders, or other chronic conditions (Devasahayam et al., 2012, Newton et al., 2010).  
Conversely, the lower proportion of UK patients with a ‘pain-only’ phenotype may indicate higher 
rates of fibromyalgia diagnoses and onward referral to specialist pain clinics. UK data showed a 
positive association between longer duration of illness and presentation with polysymptomatic 
phenotypes. If this association is a consequence of ‘accrual’ of symptoms over time (rather than an 
aetiological difference in oligo- versus polysymptomatic phenotypes), and if referral to UK 
specialist services is slower than in the Netherlands, then we would expect a higher proportion of 
UK patients to present with polysymptomatic phenotypes. We did not have data on duration of 
illness in Dutch patients with which to test the latter hypothesis. 
 
Dutch patients had lower levels of fatigue and higher levels of physical function than UK patients, 
and sex was not associated with phenotype. However, the same trends in patient-reported 
outcomes (fatigue, physical function, depression and self-efficacy) across the CFS phenotypes 
were seen in both UK and Dutch data. We do not know the extent to which our findings are 
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generalizable to ‘undetected’ CFS cases in the wider population, because both of our cohorts 
comprised patients who had access to specialist CFS services. Our analysis was based on 
presence/absence of symptoms, without consideration of symptom frequency or severity. 
Analysing symptoms by their frequency or severity might have yielded different results. 
 
Our findings in the context of other studies 
Our CFS phenotypes broadly replicate the results of earlier studies which have attempted to 
delineate symptom profiles among CFS patients or people with a CFS-like illness. Most notably, 
several studies found a polysymptomatic phenotype which affected a proportion of patients similar 
to that observed in our study. Compared with the 33% of patients assigned to this phenotype in our 
6-class solution, the proportions of polysymptomatic (labelled by some authors as ‘somatoform’) 
patients in these other studies were 27% of 565 Australian patients (Hickie et al., 1995), 32% of 
744 patients from the UK, USA and Australia (Wilson et al., 2001), and 28% of 157 patients from 
the USA (Janal et al., 2006). One study assigned a high proportion (53%) of its 646 participants to 
two polysymptomatic classes, but the cohort comprised CFS and fibromyalgia patients (Sullivan 
et al., 2002). Conversely, a lower proportion (14%) of polysymptomatics was found in a Swedish 
cohort of 5330 twins, but only 48% of this cohort had fatigue of ≥6 months’ duration (Sullivan et 
al., 2005). Given that twins who had fatigue of ≥6 months’ duration plus ≥4 of the 8 CDC 
symptoms had very high probabilities of being in this polysymptomatic class, the true proportion 
would be closer to 28%, similar to the proportion observed in our study. The Swedish twins study 
reported a 5-classes, 4 of which had symptom profiles similar to those in our UK data, namely: 
polysymptomatic, oligosymptomatic, muscle/joint pain-only, and sore throat/tender lymph nodes. 
In our sensitivity analyses, we found that obesity and sleep apnoea/hypnoea did not contribute to 
delineation of CFS phenotypes, which is inconsistent with several earlier studies (Aslakson et al., 
2009, Aslakson et al., 2006, Vollmer-Conna et al., 2006). These studies differed considerably 
from ours in methodology (LCA based on a similar set of 12 symptoms, but with the addition of 
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26 other biological and clinical measurements, many as continuous variables) and study 
population (population-based samples from Georgia and Kansas, USA, comprising CFS, 
chronically-fatigued and healthy participants). That sleep apnoea/hypnoea did not differentiate 
latent classes in our analysis may be because the Epworth Sleepiness Scale does not have high 
sensitivity and specificity for this disorder (Pataka et al., 2014, Ulasli et al., 2014), or because 
patients with this disorder were excluded by clinicians at assessment. 
 
Four of the five studies reported, as we did, that the polysymptomatic phenotype was more likely 
to occur in women, and was associated with a more severe illness of longer duration and with 
comorbid mood disorders (Hickie et al., 1995, Sullivan et al., 2005, Sullivan et al., 2002, Wilson 
et al., 2001). Other consistencies between the results from our study and other CFS latent class 
and/or factor analysis studies include evidence for musculoskeletal pain and sore throat/painful 
glands as key phenotypic delineators (Hickie et al., 2009, Janal et al., 2006, Sullivan et al., 2005). 
 
Implications for practice and future research 
The two main implications of our study are: a) post-exertional malaise, cognitive dysfunction and 
disturbed/unrefreshing sleep were near universal symptoms; and b) having made a diagnosis, 
patient profiling (subtyping) based on a set of common symptoms could form the basis for 
individualized treatment approaches. In support of the latter notion, we found substantial variation 
in patient-reported measures across our phenotypes. For example, CFS patients presenting with a 
sore throat/painful lymph node phenotype had a mean Chalder Fatigue score within 1 standard 
deviation (SD) of the mean score for adult attendees at UK general practice (14·2 ±4·6) (Cella and 
Chalder, 2010), and an SF-36 physical function score within 1 SD of the mean score for the UK 
working age population (84 ±24) (Bowling et al., 1999). These patients appear to be different 
from those presenting with a polysymptomatic phenotype. Three studies have shown that CFS 
patients who present with pain symptoms have less favourable treatment outcomes (Cella et al., 
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2011, Crawley et al., 2013, Knoop et al., 2007b). We found considerable overlap between CFS 
and fibromyalgia in our ‘full’ polysymptomatic and ‘pain-only’ phenotypes, reflecting the 
phenotypic similarity of these diseases (Sullivan et al., 2002). CFS patients with pain symptoms 
may respond to tailored interventions. For example, our ‘pain-only’ CFS phenotype was 
associated with obesity, raising the possibility that weight loss could ameliorate pain symptoms, as 
has been shown for fibromyalgia (Ursini et al., 2011). 
 
The three ‘cardinal’ symptoms may simply reflect the diagnostic criteria used in the UK and the 
Netherlands. For example, UK NICE guidelines specify that healthcare professionals should 
consider the possibility of CFS/ME if a person has fatigue with several features, including fatigue 
“characterised by post-exertional malaise and/or fatigue (typically delayed, for example by at least 
24 hours, with slow recovery over several days)” (NICE, 2007). 
 
Our next step will be to investigate associations between our CFS phenotypes and 12-month 
treatment outcomes in a follow-on study, which will also serve to replicate our phenotypes using a 
second large CFS patient sample from the same NHS services. Some of the specific factors used 
in our study and earlier studies, e.g. pain, may warrant more detailed phenotypic analysis, as has 
been done for sleep abnormalities (Gotts et al., 2013). Associations of symptom-based phenotypes 
with ‘other’ comorbidities, such as postural orthostatic tachycardia syndrome (Lewis et al., 2013), 
also need to be explored. Longitudinal models based on repeated measures of symptoms and other 
biological and clinical measurements could be used to investigate why a triggering event, such as 
an acute infection, leads to CFS in a small minority of people, to further investigate whether more 
symptoms at onset predict a chronic course or whether a chronic course leads to the development 
of more symptoms (Friedberg et al., 2000, Nisenbaum et al., 2000, Nisenbaum et al., 2004), and 
to investigate why some patients do not respond to treatment. 
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CONCLUSION 
We have identified CFS phenotypes that are consistent with earlier studies, are replicated in two 
large patient cohorts, and have potential diagnostic and prognostic utility because they are based 
on routinely-recorded CFS-related symptoms. We have shown that, among the 8-12 symptoms 
listed in the diagnostic criteria for patients in our two study cohorts, post-exertional malaise, 
cognitive dysfunction and disturbed/unrefreshing sleep could be regarded as cardinal symptoms. 
We further characterised our symptom-based CFS phenotypes in terms of their associations with 
patient characteristics, comorbidities, and patient-reported measures, thereby providing qualitative 
evidence on which to base testable hypotheses around the clinical management of CFS. 
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Table 1: Presence of symptoms among UK and Dutch adult CFS patients at time of clinical assessment 
 UK adult CFS patients Dutch adult CFS patients 
Symptom Female Male Overall Female Male Overall 
 n=5,488 n=1,553 n=7,041 n=1,036 n=356 n=1,392 
Post-exertional malaise 5,309 (96.7%) 1,485 (95.6%) 6,794 (96.5%) 916 (88.4%) 302 (84.8%) 1,218 (87.5%) 
Cognitive dysfunction 5,194 (94.6%) 1,430 (92.1%) 6,624 (94.1%) 958 (92.5%) 324 (91.0%) 1,282 (92.1%) 
Sleep disturbance/unrefreshing sleep 5,258 (95.8%) 1,454 (93.6%) 6,712 (95.3%) 1,007 (97.2%) 341 (95.8%) 1,348 (96.8%) 
Muscle pain 4,866 (88.7%) 1,269 (81.7%) 6,135 (87.1%) 700 (67.6%) 248 (69.7%) 948 (68.1%) 
Joint pain 4,237 (77.2%) 1,049 (67.6%) 5,286 (75.1%) 607 (58.6%) 201 (56.5%) 808 (58.1%) 
Headaches 4,052 (73.8%) 1,020 (65.7%) 5,072 (72.0%) 574 (55.4%) 186 (52.3%) 760 (54.6%) 
Painful lymph nodes 2,703 (49.3%) 585 (37.7%) 3,288 (46.7%) 247 (23.8%) 62 (17.4%) 309 (22.2%) 
Sore throat 3,129 (57.0%) 696 (44.8%) 3,825 (54.3%) 195 (18.8%) 56 (15.7%) 251 (18.0%) 
General malaise or ‘flu-like’ symptoms 4,042 (73.7%) 1,091 (70.3%) 5,133 (72.9%) Not recorded Not recorded Not recorded 
Dizziness 3,279 (59.8%) 815 (52.5%) 4,094 (58.2%) Not recorded Not recorded Not recorded 
Nausea 2,650 (48.3%) 549 (35.4%) 3,199 (45.4%) Not recorded Not recorded Not recorded 
Palpitations 2,038 (37.1%) 470 (30.3%) 2,508 (35.6%) Not recorded Not recorded Not recorded 
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Table 2: Factors associated with CFS phenotype (reference class = class 1 ‘oligosymptomatic’)a 
    Class 2 Class 3 Class 4 Class 5 Class 6 
  Non-throat/lymph 
polysymptomatic 
Pain-only 
(muscle/joint) 
Throat/lymph 
polysymptomatic 
Non-dizzy 
polysymptomatic 
Full polysymptomatic 
  Odds Ratio (95% CI) Odds Ratio (95% CI) Odds Ratio (95% CI) Odds Ratio (95% CI) Odds Ratio (95% CI) 
Sexb  1.82 (1.32, 2.53) 1.62 (1.18, 2.22) 1.44 (0.95, 2.18) 2.14 (1.56, 2.93) 3.75 (2.78, 5.06) 
Age group (years)c 30-39 1.11 (0.69, 1.79) 1.18 (0.73, 1.91) 1.40 (0.80, 2.45) 1.19 (0.75, 1.89) 1.12 (0.73, 1.72) 
 40-49 0.94 (0.60, 1.46) 1.30 (0.83, 2.02) 0.65 (0.36, 1.14) 1.02 (0.67, 1.56) 0.90 (0.61, 1.34) 
 50-59 0.87 (0.54, 1.41) 1.39 (0.87, 2.23) 0.47 (0.24, 0.92) 1.04 (0.66, 1.64) 0.69 (0.45, 1.07) 
 60+ 0.71 (0.42, 1.22) 0.72 (0.42, 1.25) 0.17 (0.06, 0.50) 0.43 (0.24, 0.74) 0.29 (0.17, 0.48) 
Duration of illness (years)d 1-2 1.01 (0.62, 1.65) 1.08 (0.67, 1.74) 0.75 (0.41, 1.39) 1.17 (0.74, 1.85) 1.47 (0.95, 2.28) 
 3-4 1.60 (0.93, 2.76) 1.44 (0.84, 2.48) 1.20 (0.62, 2.32) 1.27 (0.74, 2.16) 2.09 (1.27, 3.44) 
 5-10 1.02 (0.62, 1.67) 1.18 (0.73, 1.89) 0.66 (0.36, 1.24) 1.07 (0.67, 1.70) 1.70 (1.10, 2.61) 
 10+ 1.79 (1.01, 3.18) 1.76 (1.00, 3.10) 0.79 (0.37, 1.70) 1.62 (0.93, 2.81) 2.36 (1.39, 4.00) 
BMI (kg/m2)e 20-24.9 0.75 (0.42, 1.35) 1.39 (0.74, 2.61) 0.77 (0.37, 1.60) 1.09 (0.60, 1.98) 0.88 (0.52, 1.50) 
 25-29.9 0.78 (0.43, 1.44) 1.65 (0.86, 3.17) 0.74 (0.34, 1.61) 1.24 (0.66, 2.31) 0.97 (0.56, 1.70) 
 30+ 1.35 (0.67, 2.71) 2.76 (1.33, 5.74) 0.80 (0.32, 2.02) 2.25 (1.11, 4.55) 2.02 (1.06, 3.84) 
a Class 1 (reference) = oligosymptomatic; Class 2 = all symptoms except painful lymph nodes and sore throat; Class 3 = pain only (muscle and joint); Class 4 = sore throat, 
painful lymph nodes, headache and flu-like symptoms; Class 5 = all symptoms except dizziness, nausea and palpitations; Class 6 = full polysymptomatic 
b Reference category = male; c Reference category = age 18-29 years; d Reference category = up to 1 year; e Reference category <20 kg/m2
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Table 3: Associations of CFS phenotypes with comorbiditiesa 
 Odds Ratio (95% CI) Adjusted OR (95% CI)b 
Migraine   
Class 1 ‘Oligosymptomatic’ 1.00 (ref) 1.00 (ref) 
Class 2 ‘Non-throat/lymph polysymptomatic’ 2.49 (1.57, 3.94) 2.26 (1.39, 3.66) 
Class 3 ‘Pain-only’ 1.07 (0.66, 1.74) 0.94 (0.57, 1.56) 
Class 4 ‘Throat/lymph polysymptomatic’ 1.25 (0.68, 2.30) 1.18 (0.62, 2.22) 
Class 5 ‘Non-dizzy polysymptomatic’ 1.09 (0.68, 1.76) 1.02 (0.62, 1.69) 
Class 6 ‘Full polysymptomatic’ 3.70 (2.41, 5.66) 3.08 (1.97, 4.83) 
Irritable Bowel Syndrome   
Class 1 ‘Oligosymptomatic’ 1.00 (ref) 1.00 (ref) 
Class 2 ‘Non-throat/lymph polysymptomatic’ 3.33 (2.18, 5.08) 3.47 (2.20, 5.49) 
Class 3 ‘Pain-only’ 1.10 (0.70, 1.72) 1.06 (0.65, 1.72) 
Class 4 ‘Throat/lymph polysymptomatic’ 1.79 (1.05, 3.05) 1.79 (1.00, 3.21) 
Class 5 ‘Non-dizzy polysymptomatic’ 1.96 (1.29, 2.99) 1.82 (1.15, 2.89) 
Class 6 ‘Full polysymptomatic’ 5.53 (3.72, 8.21) 4.81 (3.12, 7.40) 
Depression   
Class 1 ‘Oligosymptomatic’ 1.00 (ref) 1.00 (ref) 
Class 2 ‘Non-throat/lymph polysymptomatic’ 1.37 (0.97, 1.94) 1.29 (0.88, 1.89) 
Class 3 ‘Pain-only’ 1.21 (0.85, 1.70) 1.14 (0.79, 1.66) 
Class 4 ‘Throat/lymph polysymptomatic’ 0.69 (0.43, 1.12) 0.61 (0.36, 1.05) 
Class 5 ‘Non-dizzy polysymptomatic’ 0.95 (0.68, 1.34) 0.90 (0.62, 1.30) 
Class 6 ‘Full polysymptomatic’ 1.64 (1.20, 2.25) 1.56 (1.11, 2.20) 
Anxiety   
Class 1 ‘Oligosymptomatic’ 1.00 (ref) 1.00 (ref) 
Class 2 ‘Non-throat/lymph polysymptomatic’ 1.23 (0.88, 1.72) 1.27 (0.88, 1.83) 
Class 3 ‘Pain-only’ 1.00 (0.72, 1.40) 1.02 (0.71, 1.47) 
Class 4 ‘Throat/lymph polysymptomatic’ 0.74 (0.47, 1.16) 0.75 (0.45, 1.23) 
Class 5 ‘Non-dizzy polysymptomatic’ 0.87 (0.62, 1.20) 0.87 (0.60, 1.25) 
Class 6 ‘Full polysymptomatic’ 1.55 (1.15, 2.10) 1.54 (1.11, 2.15) 
Other comorbidity   
Class 1 ‘Oligosymptomatic’ 1.00 (ref) 1.00 (ref) 
Class 2 ‘Non-throat/lymph polysymptomatic’ 2.56 (1.45, 4.51) 2.08 (1.16, 3.74) 
Class 3 ‘Pain-only’ 1.62 (0.91, 2.90) 1.34 (0.74, 2.43) 
Class 4 ‘Throat/lymph polysymptomatic’ 1.70 (0.84, 3.45) 1.45 (0.68, 3.07) 
Class 5 ‘Non-dizzy polysymptomatic’ 1.65 (0.94, 2.91) 1.60 (0.90, 2.86) 
Class 6 ‘Full polysymptomatic’ 2.38 (1.39, 4.07) 2.34 (1.35, 4.04) 
a Class 1 = oligosymptomatic; Class 2 = all symptoms except painful lymph nodes and sore throat; 
Class 3 = pain only (muscle and joint); Class 4 = sore throat, painful lymph nodes, headache and 
flu-like symptoms; Class 5 = all symptoms except dizziness, nausea and palpitations; Class 6 = full 
polysymptomatic 
b Odds Ratios (OR) adjusted for age, sex and duration of illness
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Table 4: Patient-reported measures (mean (95% CI)) in CFS phenotypesa 
 Chalder Fatigue SF36 Physical 
Function 
HADS 
Depression 
HADS Anxiety Visual Analogue 
Pain Rating 
Epworth 
Sleepiness 
Self-efficacy EQ-5D 
 (range 0 to 33) (range 0 to 100) (range 0 to 21) (range 0 to 21) (range 0 to 100) (range 0 to 24) (range 1 to 10) (range -1 to +1) 
Class 1 
‘Oligosymptomatic’ 
26.1 (25.5, 26.7) 56.4 (53.6, 59.2) 8.39 (7.95, 8.82) 8.20 (7.71, 8.69) 15.0 (13.2, 16.9) 9.01 (8.42, 9.60) 5.29 (5.08, 5.49) 0.634 (0.612, 0.656) 
Class 2 ‘Non-
throat/lymph 
polysymptomatic’ 
28.0 (27.8, 28.3) 40.3 (38.6, 42.1) 10.3 (9.96, 10.6) 10.7 (10.4, 11.1) 53.4 (51.0, 55.8) 10.7 (10.3, 11.1) 4.05 (3.92, 4.19) 0.426 (0.400, 0.452) 
Class 3 ‘Pain-only’ 27.0 (26.6, 27.3) 42.5 (40.9, 44.0) 9.65 (9.39, 9.91) 9.64 (9.36, 9.91) 56.0 (54.3, 57.8) 11.1 (10.7, 11.4) 4.43 (4.30, 4.55) 0.438 (0.418, 0.459) 
Class 4 
‘Throat/lymph 
polysymptomatic’ 
17.6 (16.4, 18.8) 63.2 (60.8, 65.5) 8.31 (7.90, 8.72) 9.02 (8.51, 9.53) 16.8 (15.0, 18.6) 9.14 (8.56, 9.72) 5.36 (5.12, 5.60) 0.618 (0.596, 0.641) 
Class 5 ‘Non-dizzy 
polysymptomatic’ 
27.3 (27.0, 27.6) 47.1 (45.5, 48.7) 9.43 (9.17, 9.68) 9.51 (9.21, 9.82) 49.7 (47.7, 51.7) 10.5 (10.1, 10.8) 4.64 (4.51, 4.78) 0.514 (0.495, 0.533) 
Class 6 ‘Full 
polysymptomatic’ 
28.8 (28.6, 29.0) 34.6 (33.5, 35.6) 11.1 (10.9, 11.3) 11.9 (11.7, 12.1) 60.9 (59.6, 62.1) 12.2 (11.9, 12.5) 3.70 (3.62, 3.79) 0.324 (0.307, 0.341) 
a Class 1 = oligosymptomatic; Class 2 = all symptoms except painful lymph nodes and sore throat; Class 3 = pain only (muscle and joint); Class 4 = sore throat, 
painful lymph nodes, headache and flu-like symptoms; Class 5 = all symptoms except dizziness, nausea and palpitations; Class 6 = full polysymptomatic. Wald-
type omnibus test of variation across the 6 classes yielded P<0.001 for all of the patient-reported measures. 
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Table 5: Characteristics of UK and Dutch adult CFS patients according to phenotype 
  UK adult CFS patientsa Dutch adult CFS patientsa 
  Class 1 (9.2%) Class 2 (37.6%) Class 3 (53.2%) Class 1 (22.6%) Class 2 (51.9%) Class 3 (25.4%) 
  oligosymptomatic pain only full polysymptomatic oligosymptomatic pain only full polysymptomatic 
  (Reference) Odds ratio (95% CI) Odds ratio (95% CI) (Reference) Odds ratio (95% CI) Odds ratio (95% CI) 
Sexb  - 1.47 (1.18, 1.83) 2.76 (2.23, 3.42) - 0.89 (0.61, 1.29) 1.14 (0.76, 1.72) 
Age group (years)c 30-39 - 1.08 (0.80, 1.46) 0.93 (0.71, 1.22) - 1.43 (0.95, 2.15) 1.32 (0.86, 2.03) 
 40-49 - 1.59 (1.18, 2.14) 1.13 (0.86, 1.48) - 2.79 (1.73, 4.51) 2.15 (1.30, 3.55) 
 50-59 - 1.89 (1.35, 2.65) 1.06 (0.78, 1.45) - 4.40 (2.30, 8.44) 3.03 (1.54, 5.95) 
 60+ - 1.48 (0.99, 2.23) 0.50 (0.33, 0.75) - 2.03 (0.76, 5.45) 0.83 (0.24, 2.87) 
        
  Mean (95% CI)d Mean (95% CI)d Mean (95% CI)d Mean (95% CI)d Mean (95% CI)d Mean (95% CI)d 
Fatigue (Chalder, range 0-33) 24.6 (24.0, 25.1) 27.0 (26.8, 27.2) 27.8 (27.6, 28.0) 23.0 (22.2, 23.7) 24.5 (24.0, 24.9) 25.8 (25.2, 26.3) 
Physical function (SF36, range 0-100) 60.4 (58.6, 62.2) 41.5 (40.5, 42.5) 39.5 (38.7, 40.3) 68.8 (66.8, 70.9) 56.9 (55.5, 58.2) 48.0 (46.1, 49.8) 
Depressione  8.30 (8.01, 8.59) 9.88 (9.71, 10.1) 10.5 (10.4, 10.7) 2.68 (2.44, 2.91) 3.15 (2.97, 3.33) 3.53 (3.28, 3.79) 
Self-efficacyf  5.32 (5.18, 5.47) 4.29 (4.22, 4.37) 4.04 (3.98, 4.11) 17.7 (17.4, 18.0) 16.9 (16.7, 17.1) 16.7 (16.4, 17.0) 
a Class 1 = ‘oligosymptomatic’; Class 2 = ‘pain only’ (muscle, joint, headache); Class 3 = ‘full’ polysymptomatic 
b Reference category = male 
c Reference category = age 18-29 years 
d Wald-type omnibus test of variation across the 3 classes yielded P<0.001 for all of the patient-reported measures 
e UK patients, HADS, range 0-21; Dutch patients, 7-item BDI-PC, range 0-21 
f UK patients, Stanford Self-Efficacy for Managing Chronic Disease 6-Item Scale, range 1-10; Dutch patients, 7-item Self-Efficacy scale, range 7-28 
.
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